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Background:  Antithymocyte globulin (ATG) is widely used as induction therapy after cardiac transplantation (OHT) for reducing the 
incidence of rejection and renal injury post transplant. The relationship between ATG induction and coronary plaque progression after OHT 
is not known.
methods:  Between March 2010 and October 2012, baseline and 1-year intravascular ultrasounds (IVUS) were performed on 87 OHT 
recipients. Progressions in maximal intimal area, maximal stenosis, average stenosis, and plaque volume on baseline and 1-year IVUS 
were measured in a blinded fashion. Plaque progression was contrasted between patients who were induced with ATG (ATG+) and those 
who were not (Control). Statistics were performed in SPSS (IBM, Armonk, New York).
results:  Mean age at OHT was 55.3±12.7 years and 31.0% of recipients were female. 32/87 (36.8%) patients were induced with ATG. 
Recipient age at OHT (Control: 55.7±12.2 years, ATG+: 54.6±13.8 years, p=0.711) and gender (Control: 16/55, ATG+: 11/32, p=0.637) 
were not statistically different between the two groups. Pre-transplant peak panel reactive antibodies (PRA) (Control: 10.4±22.7%, ATG+: 
35.7±41.2%, p=0.003), sensitization status (Control: 14/55, ATG+: 16/32, p=0.034), and post-transplant peak PRA (Control: 10.1±23.6%, 
ATG+: 35.3±36.6%, p=0.001) were significantly higher in the ATG+ group. Patients induced with ATG had significantly decreased 
progression of plaque progression by maximal intimal area (0.9±1.1 versus 2.1±2.3 mm^2/year, p=0.001), maximal stenosis (5.9±7.2 
versus 11.8±12.0 %/year, p=0.005), average stenosis (4.1±4.2 versus 6.5±6.9 %/year, p=0.043), and plaque volume (0.5±0.6 versus 
0.9±1.2 mm^3/mm/year, p=0.032).
conclusion:  Induction therapy with ATG is associated with significantly decreased plaque progression by IVUS in the first year after 
cardiac transplantation. The degree of inhibition is especially significant given the larger prevalence, in those who received ATG therapy, of 
sensitized patients at the most risk of experiencing rejection and cardiac allograft vasculopathy (CAV). Further investigation is warranted to 
examine whether ATG use can result in decreased progression of CAV.
